Cullinan Associates’s Precigen PGEN Stock Holding History

Cullinan Associates’s Portfolio PGEN Stock Details PGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-8,341	Closed	-$201K	–	201
2017 Q2	$201K	Buy	+8,341	New	+$183K	0.02%	196

Other funds holding PGEN

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Cullinan Associates's PGEN Position: Q3 2017 in Review

Cullinan Associates sold out of Precigen (PGEN) in Q3 2017, closing a stake of 8,341 shares — an estimated $201K sold.

Cullinan Associates first reported a position in PGEN in Q2 2017 and held it in 1 quarter. The position peaked at $201K in Q2 2017. 155 funds tracked by Wall St. Rank hold PGEN as of Q3 2017.

Cullinan Associates reported no remaining Precigen position as of Q3 2017 after selling out during the quarter.
Cullinan Associates sold 8,341 Precigen shares in Q3 2017, an estimated $201K.
Cullinan Associates first reported a position in Precigen in Q2 2017 and held it in 1 quarter.
Cullinan Associates's Precigen position peaked at $201K in Q2 2017.
155 funds tracked by Wall St. Rank held Precigen as of Q3 2017.

Based on Cullinan Associates's 13F filing for Q3 2017, filed 16 Oct 2017.